No new diabetes-specific approval, safety communication or guideline change appeared in today's sweep. The most recent relevant decisions are these, and none of them is new today. On 25 August the US Food and Drug Administration approved the first oral inhibitor of proprotein convertase subtilisin/kexin type 9, known as PCSK9, to lower LDL cholesterol; this class has until now been injectable only. On 11 August the agency cleared a batch of supplements to existing fixed-dose combination products, covering the linagliptin and metformin, empagliflozin and metformin, and sitagliptin and metformin families, and on 6 August a supplement to sotagliflozin. These are supplements to products already on the market rather than new indications.
The oral PCSK9 approval is the one worth registering in a diabetes clinic. Most patients with diabetes who need LDL lowering beyond a statin are currently being asked to accept an injection, and in India uptake of this class is limited by cost and by cold-chain storage as much as by clinical need. A tablet removes two of those barriers at a stroke.
Nothing changes in your prescribing today. A statin plus ezetimibe remains the backbone for raised LDL cholesterol in diabetes, and that is where escalation should still start. File the oral option mentally for the patient who declines injections, and wait to see the price and the Indian availability before mentioning it as a realistic plan to anyone.
- No new diabetes-specific regulatory action today.
- The first oral PCSK9 inhibitor is now approved in the US; previously the class was injectable only.
- The 11 August FDA actions were supplements to existing combination products, not new indications.
- Statin plus ezetimibe remains the first escalation for raised LDL cholesterol in diabetes.
- Indian availability and price for the oral PCSK9 inhibitor are unknown, so do not promise it to patients.
The statistics, in plain English
An approval notice carries no effect sizes, and that absence is itself worth reading carefully. Approval of an oral PCSK9 inhibitor tells you it lowers LDL cholesterol enough to satisfy a regulator, not that it prevents heart attacks by as much as the injectable versions do - those took dedicated outcome trials over several years to establish. When the figures do appear, the numbers to look for are the percentage reduction in LDL cholesterol against a statin background and whether any cardiovascular outcome trial has reported, not the LDL number alone.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free